FREMONT, Calif., Jan. 3 /PRNewswire/ -- Versicor, Inc. (Nasdaq: VERS)
today announced that George F. Horner III, the company's president and chief
executive officer, will provide an update on progress with its lead late-stage
product candidates, anidulafungin and dalbavancin, and its prolific research
and development collaborations at the JPMorgan H&Q 20th Annual Healthcare
Conference on Monday, January 7. His presentation will take place at
4:00 p.m. (PT) in the Elizabethan C & D Rooms at the Westin St. Francis Hotel
in San Francisco.
To join the presentation online, a live webcast will be accessible at
http://www.eventsdigital.com/events/jpmhq/healthcare2002 and archived for one month.
Versicor, Inc. is a biopharmaceutical company committed to discovering,
developing and commercializing novel, broad-spectrum antifungal and antibiotic
agents. Its lead investigational products, anidulafungin, a novel antifungal
agent, and dalbavancin, a novel antibiotic for the treatment of serious
Gram-positive infections, are in the advanced stages of clinical development.
Versicor's versatile research engine integrates industry-leading expertise in
functional genomics, automated screening and combinatorial and medicinal
chemistry. In addition, the company has research and development
collaborations with such leading pharmaceutical and anti-infective development
companies as Pharmacia Corporation, Novartis and Biosearch Italia.
This news release contains or incorporates statements that constitute
forward-looking statements that involve a number of risks and uncertainties.
These statements appear in a number of places in this news release and include
statements regarding, among other matters, the initiation, timing and results
of pending or future clinical trials, the status of ongoing proprietary or
collaborative research and other factors affecting Versicor's financial
condition or results of operations. Words such as "predict," "explore,"
"bring," "become," "believe," and "estimate" and variations of these words and
similar expressions are used in many cases to identify these forward-looking
statements. Actual events or results may differ from the company's
expectations. This includes the timing and results of clinical trials, the
outcome of proprietary and collaborative research, and the acceptance of
products in the marketplace, as well as, those risk factors listed from time
to time in reports filed with the U.S. Securities and Exchange Commission,
including but not limited to, reports on Forms S-1, 10-Q and 10-K. Versicor
will not update any forward-looking information to reflect actual results or
changes in the factors affecting the forward-looking information.
SOURCE Versicor, Inc.
 back to top
Related links:
http://www.versicor.com
CONTACT:
Dov Goldstein of Versicor, Inc.,
+1-510-739-3000, or dgoldstein@versicor.com; or Jim Weiss,
+1-415-203-0328, or weisscomm@earthlink.net, or Karen Halsey,
+1-415-272-5107, or karen.halsey@attbi.com, both of WeissCom
Partners, for Versicor, Inc.
|
